
TY  - JOUR
TI  - ILTS
JO  - Liver Transplantation
JA  - Liver Transpl
VL  - 12
IS  - 5
SN  - 1527-6465
UR  - https://doi.org/10.1002/lt.20832
DO  - doi:10.1002/lt.20832
SP  - C1
EP  - C142
PY  - 2006
ER  - 

TY  - JOUR
TI  - EACS 2019 – Abstract Book
JO  - HIV Medicine
JA  - HIV Med
VL  - 20
IS  - S9
SN  - 1464-2662
UR  - https://doi.org/10.1111/hiv.12814
DO  - doi:10.1111/hiv.12814
SP  - 3
EP  - 316
PY  - 2019
ER  - 

TY  - JOUR
TI  - 2015 Annual Meeting of the American Society for Bone and Mineral Research Seattle, WA October 9–12, 2015
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 30
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.2763
DO  - doi:10.1002/jbmr.2763
SP  - S1
EP  - S1
PY  - 2015
AB  - ABSTRACT Searchable abstracts may be found at http://www.asbmr.org/education/abstracts
ER  - 

TY  - JOUR
TI  - Published Only
JO  - Journal of Digestive Diseases
JA  - Journal of Digestive Diseases
VL  - 15
IS  - S1
SN  - 1751-2972
UR  - https://doi.org/10.1111/1751-2980.12194
DO  - doi:10.1111/1751-2980.12194
SP  - 29
EP  - 173
PY  - 2014
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Asia-Pacific Journal of Clinical Oncology
JA  - Asia‐Pac J Clin Oncol
VL  - 10
IS  - S9
SN  - 1743-7555
UR  - https://doi.org/10.1111/ajco.12332
DO  - doi:10.1111/ajco.12332
SP  - 1
EP  - 264
PY  - 2014
ER  - 

TY  - JOUR
TI  - ePresentation Sessions
JO  - European Journal of Neurology
JA  - Eur J Neurol
VL  - 26
IS  - S1
SN  - 1351-5101
UR  - https://doi.org/10.1111/ene.14018
DO  - doi:10.1111/ene.14018
SP  - 112
EP  - 346
PY  - 2019
ER  - 

TY  - JOUR
TI  - ISLH 2018 Abstracts
JO  - International Journal of Laboratory Hematology
JA  - Int. Jnl. Lab. Hem.
VL  - 40
IS  - S2
SN  - 1751-5521
UR  - https://doi.org/10.1111/ijlh.12923
DO  - doi:10.1111/ijlh.12923
SP  - 1
EP  - 165
PY  - 2018
ER  - 

TY  - JOUR
TI  - Poster - Gastroenterology
JO  - Journal of Gastroenterology and Hepatology
JA  - Journal of Gastroenterology and Hepatology
VL  - 30
IS  - S4
SN  - 0815-9319
UR  - https://doi.org/10.1111/jgh.13188
DO  - doi:10.1111/jgh.13188
SP  - 28
EP  - 159
PY  - 2015
ER  - 

TY  - JOUR
TI  - Abstracts of the 76th Annual Meeting of the Japanese Cancer Association; 2017 Sept 28-30; Yokohama, Japan
JO  - Cancer Science
JA  - Cancer Sci
VL  - 109
IS  - S1
SN  - 1347-9032
UR  - https://doi.org/10.1111/cas.13499
DO  - doi:10.1111/cas.13499
SP  - 1
EP  - 1325
PY  - 2018
ER  - 

TY  - JOUR
C7  - e25327
TI  - Oral abstracts of the 10th IAS Conference on HIV Science, 21-24 July 2019, Mexico City, Mexico
JO  - Journal of the International AIDS Society
JA  - J Intern AIDS Soc
VL  - 22
IS  - S5
SN  - 1758-2652
UR  - https://doi.org/10.1002/jia2.25327
DO  - doi:10.1002/jia2.25327
SP  - e25327
PY  - 2019
ER  - 

TY  - JOUR
AU  - Connelly, James
AU  - Pilch, N.
AU  - Oliver, M.
AU  - Jordan, C.
AU  - Fleming, J.
AU  - Meadows, H.
AU  - Baliga, P.
AU  - Nadig, S.
AU  - Twombley, K.
AU  - Shatat, I.
AU  - Taber, D.
TI  - Prediction of medication non-adherence and associated outcomes in pediatric kidney transplant recipients
JO  - Pediatric Transplantation
JA  - Pediatr Transplantation
VL  - 19
IS  - 5
SN  - 1397-3142
UR  - https://doi.org/10.1111/petr.12479
DO  - doi:10.1111/petr.12479
SP  - 555
EP  - 562
KW  - pediatric kidney transplant
KW  - medication non-adherence
KW  - risk factors
KW  - rejection
PY  - 2015
AB  - Abstract Studies have continued to evaluate risk factors associated with post-transplant non-adherence in pediatric patients. However, many of these studies fail to evaluate how risk factors can be utilized to predict MNA. The aims of this study were to (i) determine salient risk factors associated with MNA to develop an adequate predictive risk model and (ii) assess transplant outcomes based on the presence of MNA in a large, diverse cohort of pediatric KTX recipients. One hundred and seventy-five solitary pediatric KTX recipients transplanted from 1999 to 2013 were included. AA, males, older patients, those who lived in urban environments, had legal issues, and lived shorter distances from the transplant center were more likely to have MNA. Using logistic regression, a parsimonious model applying nine risk factors together was developed for predicting MNA, demonstrating a PPV of 69% and a NPV of 81%. Patients with MNA had more than twice the risk of biopsy proven acute rejection, 1.6 times the risk of hospitalization, and 1.8 times the risk of graft loss. Utilization of a predictive model to determine risk of MNA after pediatric KTX may offer clinicians the ability to efficiently and effectively monitor MNA following transplant.
ER  - 

TY  - JOUR
TI  - Poster Sessions: Liver
JO  - American Journal of Transplantation
VL  - 14
IS  - S3
SN  - 1600-6135
UR  - https://doi.org/10.1111/ajt.12892
DO  - doi:10.1111/ajt.12892
SP  - 693
EP  - 799
PY  - 2014
ER  - 

TY  - JOUR
AU  - Jairath, V.
AU  - Khanna, R.
AU  - Zou, G. Y.
AU  - Stitt, L.
AU  - Mosli, M.
AU  - Vandervoort, M. K.
AU  - D'Haens, G.
AU  - Sandborn, W. J.
AU  - Feagan, B. G.
AU  - Levesque, B. G.
TI  - Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials
JO  - Alimentary Pharmacology & Therapeutics
JA  - Aliment Pharmacol Ther
VL  - 42
IS  - 10
SN  - 0269-2813
UR  - https://doi.org/10.1111/apt.13408
DO  - doi:10.1111/apt.13408
SP  - 1200
EP  - 1210
PY  - 2015
AB  - Summary Background Patient-reported outcomes (PROs) have an increasingly important role in the evaluation of new therapies for inflammatory bowel disease. The US Food and Drug Administration has issued formal guidance to describe the role of PRO instruments in evaluation of claims for product labelling. However, no validated PRO exists for ulcerative colitis. Aim To investigate whether the PROs from the Mayo Clinic Score (MCS) for UC can be modified, to develop an interim PRO for use in clinical trials, alone or in combination with endoscopy. Methods Data from an induction trial of a mesalazine (mesalamine) formulation were used to compare effect sizes between mesalazine and placebo for PRO items (stool frequency and rectal bleeding) alone and in combination with endoscopy. The operating properties of the PRO were validated using data from a phase 2 trial of MLN02, a humanised antibody to the α4?7 integrin in patients with UC. Results A two-item PRO (PRO2) consisting of rectal bleeding = 0 and stool frequency ≤1 or ≤2, combined with an endoscopy subscore ≤1 yielded statistically significant differences between active drug and placebo. This combination yielded the most similar effect sizes and placebo rates for remission, compared to the primary trials. Use of PRO items alone yielded high placebo remission rates in both data sets, although rates were lower when the items were combined and remission defined as PRO2 = 0. Conclusion Patient-reported outcomes items derived from the Mayo Clinic Score combined with endoscopy as a co-primary endpoint may be an appropriate interim outcome measure for ulcerative colitis trials.
ER  - 

TY  - JOUR
TI  - Free Oral
JO  - HPB
JA  - HPB
VL  - 16
IS  - s2
SN  - 1365-182X
UR  - https://doi.org/10.1111/hpb.12229
DO  - doi:10.1111/hpb.12229
SP  - 128
EP  - 241
PY  - 2014
ER  - 

TY  - JOUR
TI  - Poster
JO  - Journal of Clinical Periodontology
JA  - J Clin Periodontol
VL  - 42
IS  - S17
SN  - 0303-6979
UR  - https://doi.org/10.1111/jcpe.12399
DO  - doi:10.1111/jcpe.12399
SP  - 64
EP  - 442
PY  - 2015
ER  - 

TY  - JOUR
TI  - Oral presentations
JO  - Clinical Microbiology and Infection
VL  - 16
IS  - s2
SN  - 1198-743X
UR  - https://doi.org/10.1111/j.1469-0691.2010.03238.x
DO  - doi:10.1111/j.1469-0691.2010.03238.x
SP  - S1
EP  - S132
PY  - 2010
ER  - 

TY  - JOUR
TI  - Abstracts accepted for publication only
JO  - Clinical Microbiology and Infection
VL  - 18
IS  - s3
SN  - 1198-743X
UR  - https://doi.org/10.1111/j.1469-0691.2012.03803.x
DO  - doi:10.1111/j.1469-0691.2012.03803.x
SP  - 716
EP  - 844
PY  - 2012
ER  - 

TY  - JOUR
TI  - Scientific Abstracts and Sessions
JO  - Medical Physics
JA  - Med. Phys.
VL  - 44
IS  - 6
SN  - 0094-2405
UR  - https://doi.org/10.1002/mp.12304
DO  - doi:10.1002/mp.12304
SP  - 2721
EP  - 3318
PY  - 2017
ER  - 

TY  - JOUR
TI  - Pregnancy Outcome
JO  - BJOG: An International Journal of Obstetrics & Gynaecology
JA  - BJOG: Int J Obstet Gy
VL  - 126
IS  - S1
SN  - 1470-0328
UR  - https://doi.org/10.1111/1471-0528.15636
DO  - doi:10.1111/1471-0528.15636
SP  - 115
EP  - 134
PY  - 2019
ER  - 

TY  - JOUR
TI  - AASLD Abstracts (pp. 383A–483A)
JO  - Hepatology
JA  - Hepatology
VL  - 38
IS  - S4
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.1840380506
DO  - doi:10.1002/hep.1840380506
SP  - 383A
EP  - 483A
PY  - 2003
ER  - 
